Press Releases

December 02, 2020
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide
BUFFALO, N.Y. , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex
Printer Friendly Version 
November 17, 2020
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
S potlight p oster on updated PFS and OS data from the pivotal Phase 3 clinical trial of o ral p aclitaxel in metastatic breast cancer BUFFALO, N.Y. , Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and
Printer Friendly Version 
November 05, 2020
Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update
FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and February 28, 2021 , respectively Four abstracts featuring Oral Paclitaxel accepted for presentation at San Antonio
Printer Friendly Version 
October 22, 2020
Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020
BUFFALO, N.Y. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter
Printer Friendly Version 
September 23, 2020
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. BUFFALO, N.Y. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel
Printer Friendly Version 
September 10, 2020
Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
BUFFALO, N.Y. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of
Printer Friendly Version 
September 08, 2020
Athenex, Inc. Announces Proposed Public Offering of Common Stock
BUFFALO, N.Y. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market
Printer Friendly Version 
September 08, 2020
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting Company to host conference call and webcast today at 10:30 a.m. Eastern Time SAN FRANCISCO and BUFFALO, N.Y. , Sept.
Printer Friendly Version 
September 01, 2020
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review
FDA grants Priority Review and sets PDUFA target action date of February 28, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting BUFFALO, N.Y. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to
Printer Friendly Version 
August 06, 2020
Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track Continued momentum in building commercialization infrastructure and supply chain for Oral Paclitaxel Announced two financing agreements for up to $275 million in aggregate Product sales guidance for 2020 raised to
Printer Friendly Version 
August 06, 2020
Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners
BUFFALO, N.Y. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into a $50
Printer Friendly Version 
August 04, 2020
Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
Pharmaceutical industry veteran with significant oncology clinical development expertise appointed to Board BUFFALO, N.Y. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel
Printer Friendly Version 
July 27, 2020
Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020
BUFFALO, N.Y. , July 27, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release second quarter
Printer Friendly Version 
June 23, 2020
Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel
BUFFALO, N.Y. , June 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the promotion of Teresa Bair , Esq.
Printer Friendly Version 
June 22, 2020
Athenex Announces $225 Million Loan Agreement with Oaktree
BUFFALO, N.Y. , June 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (“ Athenex” or the “Company”)  (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that
Printer Friendly Version 
June 13, 2020
Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer
Campaign features stories of hope, tears, and encouragement from a diverse group of 9 individuals with metastatic breast cancer [MBC]   New website and mobile app provide vital information and resources to help people facing MBC create a personal support network and feel less isolated BUFFALO, N.Y.
Printer Friendly Version 
May 29, 2020
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
Data are featured as an ASCO poster presentation and will be part of the Sarcoma Highlights Session on Sunday, May 31, 2020 at 3:30pm ET BUFFALO, N.Y. , May 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and
Printer Friendly Version 
May 19, 2020
Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference
BUFFALO, N.Y. , May 19, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in
Printer Friendly Version 
May 07, 2020
Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update
Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance re-affirmed Conference call & webcast today at 8:00am Eastern Time BUFFALO, N.Y. , May 07, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc.
Printer Friendly Version 
April 29, 2020
Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program
BUFFALO, N.Y. , April 29, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for its ongoing
Printer Friendly Version 
April 23, 2020
Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020
BUFFALO, N.Y. , April 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release first quarter
Printer Friendly Version 
April 09, 2020
Athenex Provides an Update on Oral Paclitaxel FDA Meeting
BUFFALO, N.Y. , April 09, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently participated in
Printer Friendly Version 
March 13, 2020
Athenex Provides a Corporate Update
BUFFALO, N.Y. , March 13, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today provides an update on the Company’s
Printer Friendly Version 
March 09, 2020
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis
PDUFA date of December 30, 2020 BUFFALO, N.Y. , March 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today
Printer Friendly Version 
March 02, 2020
Athenex’s Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis
BUFFALO, N.Y. , March 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, provided an update today that its partner,
Printer Friendly Version 
February 27, 2020
Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update
Tirbanibulin ointment NDA for actinic keratosis was submitted Oral Paclitaxel NDA submission is on track; Final FDA meeting scheduled for early April Presentation of Oral Paclitaxel Phase 3 results at SABCS received broad positive reception 43% y/y increase in product revenue and 14% y/y increase
Printer Friendly Version 
February 25, 2020
Athenex Announces Participation at the Cowen 40th Annual Health Care Conference
BUFFALO, N.Y. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that management will present at the Cowen 40 th Annual
Printer Friendly Version 
February 06, 2020
Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020
BUFFALO, N.Y. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that it will release fourth quarter and full year 2019
Printer Friendly Version 
February 03, 2020
Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma
BUFFALO, N.Y. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Today, Dr. Johnson Lau , Chairman and Chief Executive Officer of Athenex , Inc. (Nasdaq: ATNX), informed shareholders he received a notice of a proposed administrative fine of RMB 100,000 (approximately $14,300 ) from the China Securities Regulatory
Printer Friendly Version